Mesoblast (NASDAQ:MESO) Stock Price Down 8.5% – Should You Sell?

Shares of Mesoblast Limited (NASDAQ:MESO) traded down 8.5% on Monday . The company traded as low as $14.44 and last traded at $14.50. 166,270 shares traded hands during trading, a decline of 21% from the average session volume of 211,650 shares. The stock had previously closed at $15.85.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mesoblast in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Mesoblast has a consensus rating of “Moderate Buy”.

Mesoblast Trading Up 0.1%

The company has a debt-to-equity ratio of 0.11, a current ratio of 1.99 and a quick ratio of 1.77. The business’s 50 day simple moving average is $17.67 and its 200 day simple moving average is $16.89. The stock has a market cap of $1.88 billion, a P/E ratio of -16.56 and a beta of 2.17.

Mesoblast (NASDAQ:MESO) last issued its earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $25.67 million during the quarter. On average, analysts expect that Mesoblast Limited will post -0.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mesoblast

Several large investors have recently made changes to their positions in MESO. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Mesoblast by 30.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock valued at $43,000 after purchasing an additional 558 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Mesoblast by 5.4% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 14,047 shares of the company’s stock worth $226,000 after buying an additional 716 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Mesoblast by 55.6% in the third quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock valued at $46,000 after acquiring an additional 1,012 shares during the last quarter. Summit X LLC boosted its holdings in shares of Mesoblast by 0.6% in the 2nd quarter. Summit X LLC now owns 199,295 shares of the company’s stock worth $2,170,000 after acquiring an additional 1,132 shares in the last quarter. Finally, Choreo LLC grew its position in Mesoblast by 15.1% during the 4th quarter. Choreo LLC now owns 12,225 shares of the company’s stock worth $227,000 after acquiring an additional 1,600 shares during the last quarter. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.